Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 2
2014 1
2015 1
2016 1
2018 2
2019 5
2020 5
2021 2
2022 3
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Two In Cis Variants-Two Worlds Apart.
Lo YC, Narayan R, Nardi V, Lennerz JK. Lo YC, et al. Among authors: narayan r. Oncologist. 2021 Dec;26(12):997-999. doi: 10.1002/onco.13946. Epub 2021 Sep 2. Oncologist. 2021. PMID: 34407276 Free PMC article.
HLA Class I Genotype Is Associated with Relapse Risk after Allogeneic Stem Cell Transplantation for NPM1-Mutated Acute Myeloid Leukemia.
Narayan R, Niroula A, Wang T, Kuxhausen M, He M, Meyer E, Chen YB, Bhatt VR, Beitinjaneh A, Nishihori T, Sharma A, Brown VI, Kamoun M, Diaz MA, Abid MB, Askar M, Kanakry CG, Gragert L, Bolon YT, Marsh SGE, Gadalla SM, Paczesny S, Spellman S, Lee SJ. Narayan R, et al. Transplant Cell Ther. 2023 Jul;29(7):452.e1-452.e11. doi: 10.1016/j.jtct.2023.03.027. Epub 2023 Mar 29. Transplant Cell Ther. 2023. PMID: 36997024
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Brunner AM, Esteve J, Porkka K, Knapper S, Traer E, Scholl S, Garcia-Manero G, Vey N, Wermke M, Janssen JJWM, Narayan R, Fleming S, Loo S, Tovar N, Kontro M, Ottmann OG, Naidu P, Sun H, Han M, White R, Zhang N, Mohammed A, Sabatos-Peyton CA, Steensma DP, Rinne ML, Borate UM, Wei AH. Brunner AM, et al. Among authors: narayan r. Am J Hematol. 2024 Feb;99(2):E32-E36. doi: 10.1002/ajh.27161. Epub 2023 Nov 22. Am J Hematol. 2024. PMID: 37994196 Clinical Trial.
First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Narayan R, Piérola AA, Donnellan WB, Yordi AM, Abdul-Hay M, Platzbecker U, Subklewe M, Kadia TM, Alonso-Domínguez JM, McCloskey J, Bradford K, Curtis M, Daskalakis N, Guttke C, Safer K, Hiebert B, Murphy J, Li X, Duchin K, Esteban D. Narayan R, et al. Clin Transl Sci. 2024 Mar;17(3):e13742. doi: 10.1111/cts.13742. Clin Transl Sci. 2024. PMID: 38494922 Free PMC article. Clinical Trial.
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.
Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, Mims AS, DeFilipp Z, El-Jawahri A, McAfee SL, Brunner AM, Narayan R, Knight LW, Kelley D, Bottoms AS, Perry LH, Wahl JL, Brock J, Breton E, Ho VT, Chen YB. Fathi AT, et al. Among authors: narayan r. Blood Adv. 2022 Nov 22;6(22):5857-5865. doi: 10.1182/bloodadvances.2022008632. Blood Adv. 2022. PMID: 36150050 Free PMC article. Clinical Trial.
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.
How J, Ren S, Lombardi-Story J, Bergeron M, Foster J, Amrein PC, Brunner AM, Fathi AT, Hock H, Khachatryan A, Kikuchi H, Ng MR, Moran J, Narayan R, Neuberg D, Ramos A, Som T, Vartanian M, Chen YB, Duda DG, Hobbs GS. How J, et al. Among authors: narayan r. EJHaem. 2022 Mar 6;3(2):434-442. doi: 10.1002/jha2.408. eCollection 2022 May. EJHaem. 2022. PMID: 35846042 Free PMC article.
23 results